2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Levy discusses key research efforts with targeted therapies for patients with lung cancer who harbor NTRK, KRAS, and HER2 aberrations.
Welcome to OncLive On AirTM! I’m your host today, Jessica Hergert.
OncLive On AirTM is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Bayer, we had the pleasure of speaking with Benjamin P. Levy, MD, an associate professor of oncology and clinical director of Medical Oncology at Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, to discuss exciting research with targeted therapies for patients with lung cancer who harbor molecular abberations.
In our exclusive interview, Levy discussed recent advances in NTRK-, KRAS-, and HER2-altered lung cancer.